Evidence map›Paper›PMID 34867390›Full record

ArticleFrontiers in pharmacology2021

Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells.

Oghenemega Okoloko, Elizabeth R Vanderwall, Lucille M Rich, Maria P White, Stephen R Reeves, Whitney E Harrington, Kaitlyn A Barrow, Jason S Debley

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Oghenemega OkolokoCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, United States.
Elizabeth R VanderwallCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, United States.
Lucille M RichCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, United States.
Maria P WhiteCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, United States.
Stephen R ReevesCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, United States.
Whitney E HarringtonCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, United States.
Kaitlyn A BarrowCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, United States.
Jason S DebleyCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, United States.
Seattle Children's Hospital · US

Funding

Impact of Heterogeneous Airway Epithelial ACE2 Expression and Interferon Responses on SARS-CoV2 Infectivity and ReplicationK24AI150991 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI DEBLEY, JASON S · 2020 to 2024
$1.2M
The Effect of Maternal Cells on Infant ImmunityK08AI135072 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI HARRINGTON, WHITNEY ELIZABETH · 2018 to 2022
$854k
NIAID NIH HHS K08 AI135072NIAID NIH HHS K24 AI150991
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ACE2airwayangiotensin-converting eitzyme inhibitorsangiotensin II (A II) receptor antagonistscaptoprilepitheliumlosartanSARS—CoV—2

Identifiers

PMID34867390
PMCPMC8641911
OpenAlexW3216536698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.